Skip to content

Tarsus Pharmaceuticals

US · TARS #2389 by market cap Listed 2020
73.01 -4.66 -6.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $97
    Market Newswire · 2026/11/6
  • Rating change
    William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
    Market Newswire · 2026/8/12
  • Rating change
    Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $105
    Market Newswire · 2026/9/9
  • Rating change
    Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/8/12
  • Rating change
    LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $98
    Market Newswire · 2026/8/4
  • A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $97 to $106
    Market Newswire · 2026/11/5
  • Rating change
    BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $84
    Market Newswire · 2026/10/12
  • Rating change
    Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $94
    Market Newswire · 2026/10/29
  • Rating change
    Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/8/12
  • Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/11/11
  • Rating change
    Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110
    Market Newswire · 2026/9/17
  • Company notice
    SHOUCHENG: VOLUNTARY ANNOUNCEMENT - REGARDING THE INVESTMENT IN TARS
    HKEX · 2026/4/16
  • Rating change
    Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/8/7
  • Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q3 Loss $14.40, Vs. FactSet Est of $1.46 Loss
    MT Newswires · 2026/11/4
  • Rating change
    LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104
    Market Newswire · 2026/8/8
  • Rating change
    Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/2
  • Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $102
    Market Newswire · 2026/11/6
  • Rating change
    H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/8/7
  • Rating change
    Goldman Sachs Upgrades Tarsus Pharmaceuticals(TARS.US) to Buy Rating, Raises Target Price to $116
    Market Newswire · 2026/9/24
  • Rating change
    Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89
    Market Newswire · 2026/7/22
  • Rating change
    Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $97
    Market Newswire · 2026/7/22
  • Rating change
    Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $98
    Market Newswire · 2026/7/31
  • Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/10/12
  • Rating change
    Oppenheimer Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $97
    Market Newswire · 2026/7/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

Tarsus Pharmaceuticals discussion 0 comments

Add a comment